Clinical implications of hepatic steatosis in patients with chronic hepatitis C: A multicenter study of U.S. veterans

Ke Qin Hu, Sue L. Currie, Hui Shen, Ramsey C. Cheung, Samuel B. Ho, Edmund J. Bini, John D. McCracken, Tim Morgan, Norbert Bräu, Warren N. Schmidt, Lennox J Jeffers, Teresa L. Wright

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Studies have indicated a high prevalence of hepatic steatosis in patients with chronic hepatitis C (CHC). To address the impact of steatosis on the clinical course of CHC and treatment response requires large multicenter studies. The present study analyzed hepatitis C virus (HCV)-infected veterans enrolled in a U.S. Veteran Administration multicenter study of the epidemiology and response to interferon α-2b and ribavirin treatment. Of the 357 patients, 97.1% were males, with a mean age of 48.7±6.4 years, and 184 (51.5%) had hepatic steatosis. The mean body mass index (BMI) was 29.3±5.2 kg/m2, including 37.1% who were obese (BMI, ≥30 kg/m2). Stage III-IV fibrosis was present in 111 of 334 (33.3%) of the patients. After adjusting for age, race, and history of alcohol use in the past 12 months, only stage III-IV fibrosis was independently and significantly associated with hepatic steatosis (P=0.03). There was a trend of association between obesity and steatosis independent of the other factors. Only HCV genotype was independently associated with a sustained virological response (SVR) to interferon α-2b and ribavirin treatment after adjusting for age, alcohol use, steatosis, BMI, stage III-IV fibrosis, serum AFP, and HCV load. In conclusion, analyses of our multicenter trial data demonstrated that the prevalence of hepatic steatosis is 51.5% in HCV-infected U.S. veterans. We found that steatosis is independently associated with stage III-IV fibrosis. However, only HCV genotype, and not steatosis, obesity, or stage III-IV fibrosis, was associated with SVR to interferon α-2b and ribavirin treatment.

Original languageEnglish
Pages (from-to)570-578
Number of pages9
JournalDigestive Diseases and Sciences
Volume52
Issue number2
DOIs
StatePublished - Feb 1 2007
Externally publishedYes

Fingerprint

Veterans
Chronic Hepatitis C
Hepacivirus
Multicenter Studies
Fibrosis
Ribavirin
Liver
Interferons
Body Mass Index
Obesity
Genotype
Alcohols
United States Department of Veterans Affairs
Therapeutics
Epidemiology
Serum

Keywords

  • Body mass index
  • Chronic hepatitis C
  • Hepatic fibrosis
  • Hepatic steatosis
  • Hepatitis C virus
  • Obesity

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Clinical implications of hepatic steatosis in patients with chronic hepatitis C : A multicenter study of U.S. veterans. / Hu, Ke Qin; Currie, Sue L.; Shen, Hui; Cheung, Ramsey C.; Ho, Samuel B.; Bini, Edmund J.; McCracken, John D.; Morgan, Tim; Bräu, Norbert; Schmidt, Warren N.; Jeffers, Lennox J; Wright, Teresa L.

In: Digestive Diseases and Sciences, Vol. 52, No. 2, 01.02.2007, p. 570-578.

Research output: Contribution to journalArticle

Hu, KQ, Currie, SL, Shen, H, Cheung, RC, Ho, SB, Bini, EJ, McCracken, JD, Morgan, T, Bräu, N, Schmidt, WN, Jeffers, LJ & Wright, TL 2007, 'Clinical implications of hepatic steatosis in patients with chronic hepatitis C: A multicenter study of U.S. veterans', Digestive Diseases and Sciences, vol. 52, no. 2, pp. 570-578. https://doi.org/10.1007/s10620-006-9418-4
Hu, Ke Qin ; Currie, Sue L. ; Shen, Hui ; Cheung, Ramsey C. ; Ho, Samuel B. ; Bini, Edmund J. ; McCracken, John D. ; Morgan, Tim ; Bräu, Norbert ; Schmidt, Warren N. ; Jeffers, Lennox J ; Wright, Teresa L. / Clinical implications of hepatic steatosis in patients with chronic hepatitis C : A multicenter study of U.S. veterans. In: Digestive Diseases and Sciences. 2007 ; Vol. 52, No. 2. pp. 570-578.
@article{36d50989a54f4e3c86e81a010bc4ff09,
title = "Clinical implications of hepatic steatosis in patients with chronic hepatitis C: A multicenter study of U.S. veterans",
abstract = "Studies have indicated a high prevalence of hepatic steatosis in patients with chronic hepatitis C (CHC). To address the impact of steatosis on the clinical course of CHC and treatment response requires large multicenter studies. The present study analyzed hepatitis C virus (HCV)-infected veterans enrolled in a U.S. Veteran Administration multicenter study of the epidemiology and response to interferon α-2b and ribavirin treatment. Of the 357 patients, 97.1{\%} were males, with a mean age of 48.7±6.4 years, and 184 (51.5{\%}) had hepatic steatosis. The mean body mass index (BMI) was 29.3±5.2 kg/m2, including 37.1{\%} who were obese (BMI, ≥30 kg/m2). Stage III-IV fibrosis was present in 111 of 334 (33.3{\%}) of the patients. After adjusting for age, race, and history of alcohol use in the past 12 months, only stage III-IV fibrosis was independently and significantly associated with hepatic steatosis (P=0.03). There was a trend of association between obesity and steatosis independent of the other factors. Only HCV genotype was independently associated with a sustained virological response (SVR) to interferon α-2b and ribavirin treatment after adjusting for age, alcohol use, steatosis, BMI, stage III-IV fibrosis, serum AFP, and HCV load. In conclusion, analyses of our multicenter trial data demonstrated that the prevalence of hepatic steatosis is 51.5{\%} in HCV-infected U.S. veterans. We found that steatosis is independently associated with stage III-IV fibrosis. However, only HCV genotype, and not steatosis, obesity, or stage III-IV fibrosis, was associated with SVR to interferon α-2b and ribavirin treatment.",
keywords = "Body mass index, Chronic hepatitis C, Hepatic fibrosis, Hepatic steatosis, Hepatitis C virus, Obesity",
author = "Hu, {Ke Qin} and Currie, {Sue L.} and Hui Shen and Cheung, {Ramsey C.} and Ho, {Samuel B.} and Bini, {Edmund J.} and McCracken, {John D.} and Tim Morgan and Norbert Br{\"a}u and Schmidt, {Warren N.} and Jeffers, {Lennox J} and Wright, {Teresa L.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1007/s10620-006-9418-4",
language = "English",
volume = "52",
pages = "570--578",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Plenum Publishers",
number = "2",

}

TY - JOUR

T1 - Clinical implications of hepatic steatosis in patients with chronic hepatitis C

T2 - A multicenter study of U.S. veterans

AU - Hu, Ke Qin

AU - Currie, Sue L.

AU - Shen, Hui

AU - Cheung, Ramsey C.

AU - Ho, Samuel B.

AU - Bini, Edmund J.

AU - McCracken, John D.

AU - Morgan, Tim

AU - Bräu, Norbert

AU - Schmidt, Warren N.

AU - Jeffers, Lennox J

AU - Wright, Teresa L.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Studies have indicated a high prevalence of hepatic steatosis in patients with chronic hepatitis C (CHC). To address the impact of steatosis on the clinical course of CHC and treatment response requires large multicenter studies. The present study analyzed hepatitis C virus (HCV)-infected veterans enrolled in a U.S. Veteran Administration multicenter study of the epidemiology and response to interferon α-2b and ribavirin treatment. Of the 357 patients, 97.1% were males, with a mean age of 48.7±6.4 years, and 184 (51.5%) had hepatic steatosis. The mean body mass index (BMI) was 29.3±5.2 kg/m2, including 37.1% who were obese (BMI, ≥30 kg/m2). Stage III-IV fibrosis was present in 111 of 334 (33.3%) of the patients. After adjusting for age, race, and history of alcohol use in the past 12 months, only stage III-IV fibrosis was independently and significantly associated with hepatic steatosis (P=0.03). There was a trend of association between obesity and steatosis independent of the other factors. Only HCV genotype was independently associated with a sustained virological response (SVR) to interferon α-2b and ribavirin treatment after adjusting for age, alcohol use, steatosis, BMI, stage III-IV fibrosis, serum AFP, and HCV load. In conclusion, analyses of our multicenter trial data demonstrated that the prevalence of hepatic steatosis is 51.5% in HCV-infected U.S. veterans. We found that steatosis is independently associated with stage III-IV fibrosis. However, only HCV genotype, and not steatosis, obesity, or stage III-IV fibrosis, was associated with SVR to interferon α-2b and ribavirin treatment.

AB - Studies have indicated a high prevalence of hepatic steatosis in patients with chronic hepatitis C (CHC). To address the impact of steatosis on the clinical course of CHC and treatment response requires large multicenter studies. The present study analyzed hepatitis C virus (HCV)-infected veterans enrolled in a U.S. Veteran Administration multicenter study of the epidemiology and response to interferon α-2b and ribavirin treatment. Of the 357 patients, 97.1% were males, with a mean age of 48.7±6.4 years, and 184 (51.5%) had hepatic steatosis. The mean body mass index (BMI) was 29.3±5.2 kg/m2, including 37.1% who were obese (BMI, ≥30 kg/m2). Stage III-IV fibrosis was present in 111 of 334 (33.3%) of the patients. After adjusting for age, race, and history of alcohol use in the past 12 months, only stage III-IV fibrosis was independently and significantly associated with hepatic steatosis (P=0.03). There was a trend of association between obesity and steatosis independent of the other factors. Only HCV genotype was independently associated with a sustained virological response (SVR) to interferon α-2b and ribavirin treatment after adjusting for age, alcohol use, steatosis, BMI, stage III-IV fibrosis, serum AFP, and HCV load. In conclusion, analyses of our multicenter trial data demonstrated that the prevalence of hepatic steatosis is 51.5% in HCV-infected U.S. veterans. We found that steatosis is independently associated with stage III-IV fibrosis. However, only HCV genotype, and not steatosis, obesity, or stage III-IV fibrosis, was associated with SVR to interferon α-2b and ribavirin treatment.

KW - Body mass index

KW - Chronic hepatitis C

KW - Hepatic fibrosis

KW - Hepatic steatosis

KW - Hepatitis C virus

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=33846839518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846839518&partnerID=8YFLogxK

U2 - 10.1007/s10620-006-9418-4

DO - 10.1007/s10620-006-9418-4

M3 - Article

C2 - 17226072

AN - SCOPUS:33846839518

VL - 52

SP - 570

EP - 578

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 2

ER -